Repligen (NASDAQ:RGEN – Get Free Report) had its price objective dropped by KeyCorp from $240.00 to $210.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. KeyCorp’s price objective would indicate a potential upside of 53.80% from the company’s previous close. KeyCorp also issued estimates for Repligen’s Q4 2023 earnings at $0.31 EPS and FY2023 earnings at $1.70 EPS.
Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $180.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 17th. Stephens boosted their target price on Repligen from $180.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, August 3rd. Royal Bank of Canada reiterated an “outperform” rating and set a $191.00 price target on shares of Repligen in a research note on Wednesday, September 6th. Wells Fargo & Company started coverage on Repligen in a research note on Thursday, July 20th. They set an “overweight” rating and a $185.00 price target on the stock. Finally, Craig Hallum dropped their price target on Repligen from $207.00 to $200.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.50.
Repligen Trading Up 3.9 %
Repligen (NASDAQ:RGEN – Get Free Report) last announced its earnings results on Tuesday, October 31st. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.09. Repligen had a return on equity of 6.12% and a net margin of 17.29%. The firm had revenue of $141.20 million for the quarter, compared to the consensus estimate of $140.68 million. During the same period in the previous year, the business earned $0.77 EPS. The firm’s revenue for the quarter was down 29.6% on a year-over-year basis. Research analysts predict that Repligen will post 1.73 EPS for the current year.
In other news, Director Karen A. Dawes sold 850 shares of the business’s stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $171.38, for a total value of $145,673.00. Following the completion of the transaction, the director now owns 83,741 shares of the company’s stock, valued at approximately $14,351,532.58. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.10% of the company’s stock.
Hedge Funds Weigh In On Repligen
Several institutional investors and hedge funds have recently modified their holdings of RGEN. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Repligen by 120.0% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 209 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 114 shares during the period. Fortis Capital Advisors LLC acquired a new position in Repligen in the 4th quarter worth about $35,000. Clearstead Advisors LLC acquired a new position in Repligen in the 1st quarter worth about $38,000. Park Place Capital Corp raised its holdings in Repligen by 90.2% in the 3rd quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 120 shares during the period. Finally, Whittier Trust Co. raised its holdings in Repligen by 108.6% in the 1st quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 126 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
- Five stocks we like better than Repligen
- 3 Monster Growth Stocks to Buy Now
- A bullish storm is brewing for cloud stocks
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is Extreme Networks’ forecast a sign of industry woes?
- How to Start Investing in Penny Stocks
- Profits come after ignorance Is highest: A PayPal story
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.